<i>In Vitro</i> Activity of the Ultrabroad-Spectrum-Beta-Lactamase Inhibitor QPX7728 against Carbapenem-Resistant <i>Enterobacterales</i> with Varying Intrinsic and Acquired Resistance Mechanisms
Kirk Nelson, Debora Rubio-Aparicio, Dongxu Sun, Michael Dudley, Olga Lomovskaya
Abstract
QPX7728 is an investigational ultrabroad-spectrum-beta-lactamase inhibitor (BLI) with potent inhibition of key serine and metallo-beta-lactamases. QPX7728 enhances the potency of many beta-lactams, including carbapenems, in isogenic strains of Gram-negative bacteria producing various beta-lactamases. The potency of meropenem alone and in combination with QPX7728 (tested at fixed concentrations of 1 to 16 μg/ml) was tested against 598 clinical isolates of carbapenem-resistant Enterobacterales (CRE).
Topics & Concepts
MeropenemPotencyCarbapenemImipenemMicrobiologyKlebsiella pneumoniaeCeftazidimeBiologyAntibioticsPharmacologyChemistryAntibiotic resistanceBacteriaIn vitroPseudomonas aeruginosaBiochemistryEscherichia coliGeneticsGeneAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPharmaceutical and Antibiotic Environmental Impacts